Introduction
Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS) are 'protein misfolding disorders' that exhibit common features of misfolded, aggregation-prone proteins and selective cell loss in the mature nervous system (Muchowski and Wacker 2005; Haass and Selkoe 2007; Asea and Brown 2008; Brown 2008; Neef et al. 2011 ). These neurodegenerative diseases impact different regions of the brain. Alzheimer's disease affects the cerebral cortex triggering memory loss and dementia (Martin 1999; Duyckaerts et al. 2009; Stranahan and Mattson 2010 ). Parkinson's disease is characterized by a loss of dopaminergic cells in the substantia nigra and is accompanied by muscle rigidity, brandykinesia and resting tremor (Schapira and Olanow 2004; Parent and Parent 2010) . Cells in the spinal cord are selectively lost in ALS, resulting in progressive muscle wasting and weakness, culminating in paralysis and respiratory failure (Bruijn et al. 2004; Barber and Shaw 2010) .
These neurodegenerative 'protein misfolding disorders' differ widely in frequency in the human population. Alzheimer's disease is 133-fold more frequent than ALS and 4-fold more frequent than Parkinson's disease (Martin 1999; Bruijn et al. 2004; Schapira and Olanow 2004; Chen and Brown 2007) . Heat shock proteins provide a line of defense against misfolded, aggregation-prone proteins (Muchowski and Wacker 2005; Brown 2007 Brown , 2008 Asea and Brown 2008; Neef et al. 2011) . We have suggested that differing levels of constitutively expressed heat shock proteins Hsc70 (product of the HSPA8 gene) and Hsp27 (product of the HSPB1 gene) in neural cell populations confer a variable buffering capacity against protein misfolding disorders that correlates with the relative frequencies of these neurodegenerative diseases (Chen and Brown 2007) . The defense capacity against protein misfolding disorders is higher in the spinal cord cells because of their elevated levels of constitutively expressed Hsc70 and Hsp27, compared to dopaminergic cells in the substantia nigra, which in turn have a higher defense capacity compared to cells in the cerebral cortex of the brain. The levels of these constitutively expressed Hsps correlate with the lower frequency of ALS, a disease that affects cells in the spinal cord, followed by a higher disease frequency for Parkinson's that affects cells in the sustantia nigra and an even higher frequency for Alzheimer's disease that impacts cells in the cerebral cortex.
We have suggested that Alzheimer's disease may exhibit a higher relative frequency due to low levels of Hsc70 and Hsp27 in cell populations in the cerebral cortex that results in a reduced defense capacity against protein misfolding compared to cell populations affected in ALS that exhibit higher levels of these potentially beneficial proteins (Chen and Brown 2007) . Neural cells may rely on their constitutive levels of Hsc70 and Hsp27 as a 'preprotection' mechanism for defense against protein misfolding triggered by stressful stimuli or that associated with neurodegenerative diseases. This suggests that a therapeutic strategy to counter Alzheimer's disease, which is characterized by low constitutive Hsc70 and Hsp27 in impacted cell populations, is the enhancement of the buffer capacity of these cells against protein misfolding by induction of Hsp70 and Hsp27. Hsp70, an inducible protein of the Hsp70 family, shares close to 90 % amino acid homology with constitutively expressed Hsc70 and exhibits overlapping biochemical properties (Daugaard et al. 2007; Brocchieri et al. 2008; Kabani and Martineau 2008) .
In the present report, we examine the ability of celastrol and classical heat shock treatment to induce Hsps in cultures derived from the cerebral cortices. Celastrol was selected because it has been identified as a potential neuroprotective candidate in a collaborative drug screen aimed at identifying therapeutic agents against neurodegenerative diseases (Abbott 2002; Heemskerk et al. 2002) . Cortical cultures were employed for investigation as cells in the cerebral cortex of the brain are selectively affected during Alzheimer's disease (Martin 1999; Duyckaerts et al. 2009; Stranahan and Mattson 2010) and because previous work has suggested that agents that are effective in countering protein aggregation in established neural cell lines, such as PC12 cells, may not be effective on cortical cells in the nervous system that are impacted during Alzheimer's disease (Zhang et al. 2012) . Cortical cultures have been used as a model system to investigate aging of the nervous system (Lesuisse and Martin 2002) .
Materials and methods

Cortical cultures
Primary cortical cultures were prepared from cerebral cortices of 19-day-old embryonic rats (E19). Timed pregnant SpragueDawley rats were obtained from Charles River Laboratories (Saint-Constant, QC, Canada). E1 was considered as the day on which a vaginal plug was observed. Cerebral cortices were gently dissociated with a plastic pipette after digestion with trypsin (TripLE, Invitrogen, Burlington, ON, Canada) at 37°C. Dissociated cells were resuspended in minimal essential medium (Gibco, Burlington, ON, Canada) supplemented with 10 % fetal calf serum, 5.56 mM glucose and 2 mM glutamine. Cell viability was assessed by trypan blue exclusion, and live cells were counted and plated at a final density of 1.8×10 5 cells/cm 2 on poly-ornithine (Sigma, Mississauga, ON, Canada) coated culture dishes (Sarstedt, Montreal, QC, Canada). Cultures were incubated at 37°C in an atmosphere of 5 % CO 2 in Neurobasal media with B27 supplement (Gibco) for the specified 'days in vitro' (DIV) of culture before treatment with celastrol or heat shock. All procedures using animals were approved by the Animal Care Committee of the University of Toronto and were in accordance with the guidelines established by the Canadian Council on Animal Care.
Heat shock and celastrol treatments
For temperature elevation, cortical cultures were heat shocked at 43°C for 10 min and subsequently incubated at 37°C for 24 h prior to analysis by immunoblotting. Cultures were incubated in the presence of celastrol at the specified concentrations for 24 h prior to analysis by immunoblotting. Celastrol was obtained from Gaia Chemical Corporation (Gaylordsville, CT, USA) and dissolved in DMSO as the vehicle. Celastrol concentration up to 1.75 μM did not affect cell viability assayed using CellTrace calcein violet AM (Invitrogen, Burlington, ON, Canada) in combination with LIVE/DEAD fixable blue dead cell stain (Invitrogen).
Western blotting
Cortical cultures were solubilized in Laemmli buffer and boiled for 20 min. Lowry assays were performed for protein quantification (Peterson 1977) . Equal loadings of 30 μg of protein per lane were separated by 12 % SDS-PAGE using the Mini-PROTEAN 3 Electrophoresis Module Assembly (Bio-Rad Laboratories, Hercules, CA) with a stacking gel of 4 %, using the standard buffer system of Laemmli before transfer to nitrocellulose membranes. Western blotting was performed with antibodies specific to Hsp70 (SPA-810, StressGen Biotechnologies, BC, Canada), Hsp32 (OSA-111, StressGen) and Hsp27 (SPA-801, StressGen) (Chow and Brown 2007; Chow et al. 2010 ). Anti-β-tubulin antibody (MAB3408, Chemicon, Temecula, CA, USA) was employed to detect tubulin as loading control. Horseradish peroxidaseconjugated secondary antibodies (Sigma) were detected by enhanced chemiluminescence assay (Amersham, Piscataway, NJ, USA). Western blots representative of three experimental repeats are shown.
Results
Induction of Hsp70 in cortical cultures by celastrol
The ability of celastrol and classical heat shock treatment to induce Hsp70 in cortical cultures was investigated. Previous investigations using cortical cultures as a model system to study aging of the nervous system have employed cultures grown for variable DIV (Lesuisse and Martin 2002) . The present study was therefore carried out at DIV6, DIV10 and DIV13. With increasing DIV, cortical cultures demonstrate progressive development, reaching maturity within 2 weeks of culture (Lesuisse and Martin 2002) .
Induction of Hsp70 in cortical cultures was observed at 1.25 and 1.75 μM celastrol, dosages that did not affect cell viability (see "Materials and methods"). Hsp70 induction was apparent at DIV13 but not at DIV6 and DIV10. In contrast, classical heat shock did not induce Hsp70 at any culture age that was examined.
Induction of Hsp27 in cortical cultures
As shown in Fig. 2 , celastrol triggered a robust induction of Hsp27 in cortical cultures at DIV13, a weaker induction at DIV10 and no detectable signal at DIV6. Induction of Hsp27 at DIV13 was observed at a lower dosage of celastrol (0.75 μM) compared to that required to induce Hsp70 (1.25 μM) (compare Figs. 1 and 2) . Interestingly, heat shock treatment induced Hsp27 at DIV13 but not DIV6 and DIV10, whereas Hsp70 was not induced by heat shock at any DIV examined.
Induction of Hsp32 in cortical cultures by celastrol and heat shock
Celastrol induced Hsp32 at all DIV stages that were examined, as did heat shock (Fig. 3) , whereas induction of Hsp70 by celastrol was observed only at the later stage of DIV13 and Hsp27 at DIV10 and 13. Heat shock also induced Hsp32 at all three culture stages, whereas heat shock did not induce Hsp70 at any stage and induced Hsp27 only at DIV13. Basal levels of Hsp32 were apparent at DIV10 and DIV13 (NT and DMSO lanes).
Discussion
Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and ALS, exhibit the common feature of accumulation of misfolded, aggregation-prone proteins, impact different regions of the nervous system and differ greatly in frequency in the human population (Selkoe 2003; Forman (Martin 1999; Bruijn et al. 2004; Schapira and Olanow 2004; Chen and Brown 2007) .
We have suggested that differing levels of the constitutively expressed heat shock proteins Hsc70 and Hsp27 in neural cell populations confer a variable buffering capacity against protein misfolding disorders that correlates with the relative frequencies of these neurodegenerative diseases (Chen and Brown 2007) . The high frequency of Alzheimer's disease correlates with a low level of Hsc70 and Hsp27 in cells in the cerebral cortex that are affected in this disease. Whereas the low frequency of ALS correlates with a high level of Hsc70 and Hsp27 conferring enhanced buffering capacity against protein misfolding disorder in cells in the spinal cord that are impacted in ALS. This suggests that an approach to countering Alzheimer's disease is the enhancement of the buffering capacity of cerebral cortical cells against protein misfolding by induction of Hsps.
In this report, we demonstrate that celastrol, but not classical heat shock treatment, is effective in inducing a set of neuroprotective Hsps in cortical cultures, including Hsp70, Hsp27 and Hsp32. Cortical cultures were specifically selected because (1) cells in the cerebral cortex are targeted in Alzheimer's disease (Martin 1999; Duyckaerts et al. 2009; Stranahan and Mattson 2010) , (2) cortical cells exhibit low levels of constitutively expressed Hsc70 and Hsp27 (Chen and Brown 2007) and (3) agents effective in countering protein aggregation in established neural cell lines, such as the rat pheochromocytoma PC12 cells, may not be effective in cortical cells in the nervous system that are impacted in Alzheimer's disease (Zhang et al. 2012) . Celastrol has been reported to induce Hsps by acting on HSF1 (Westerheide et al. 2004) . Our previous studies have demonstrated that HSF1 is present in cerebral cortical neurons (Brown and Rush 1999) .
Celastrol has been identified as a potential neuroprotective candidate in a collaborative drug screen aimed at identifying therapeutic agents against neurodegenerative diseases from a panel of existing drugs and natural products (Abbott 2002; Heemskerk et al. 2002) . Candidates were scored on their ability to suppress aspects associated with neurodegenerative diseases such as protein aggregation. Celastrol, a quinine methide triterpene, is extracted from the vine Tripterygium wilfordii of the Celastraceae family (Zhou 1991) . It has been used in traditional Chinese medicine for the treatment of various illnesses (Tao et al. 2002; Pinna et al. 2004) . Celastrol is a proteosome inhibitor that targets the chymotrypsin-like activity of the proteosome (Yang et al. 2006) . Other proteosome inhibitors, such as MG132 and lactacystin, have also been shown to induce Hsps (Choy et al. 2011; Kim et al. 2011) .
Interestingly, our results indicate that the profile of Hsps induced by celastrol in cortical cultures is influenced by the time period ('days in vitro' or DIV) that the cortical cells were grown in culture. Hsp70, Hsp27 and Hsp32 are all inducible by celastrol at DIV13 when the cortical cultures have reached maturity, but this set of Hsps is not inducible by celastrol in immature cultures at DIV6 and DIV10 (summarized in Fig. 4 ). Alzheimer's disease is a 'protein misfolding disorder' of cells in the cerebral cortex of the mature brain (Selkoe 2004) ; hence, the inducibility of a set of neuroprotective Hsps in mature cortical cultures at DIV13 suggests that celastrol could be a potential agent to counter Alzheimer's, a neurodegenerative disease of the adult brain. Our results demonstrate that celastrol induces Hsp27 and Hsp32 in addition to Hsp70 in mature cortical cultures. The neuroprotective features of these Hsps have received less attention compared to Hsp70 (Asea and Brown 2008). However, Hsp27 has been demonstrated to be involved in neuronal survival and neurite outgrowth (Hong et al. 2009; Williams and Mearow 2011) . Neuroprotective effects of Hsp27 against ethanol toxicity have been reported (Toth et al. 2010) , and Hsp27 protects cortical neurons from beta-amyloid mediated toxicity (King et al. 2009 ). Hsp27 exhibits neuroprotective effects in animal models of neurodegenerative diseases and following nerve injury (Read and Gorman 2009) .
Our studies also indicate that celastrol induces a particularly robust induction of Hsp32, a protein that has received comparatively little attention in neurodegenerative diseases compared to Hsp70 (Asea and Brown 2008) . Hsp32 (also known as heme oxygenase-1) is involved in the removal of cytotoxic heme by converting it to carbon monoxide (CO), biliverdin and ferrous iron (Tenhunen et al. 1969) . CO is a signalling molecule that has pro-survival and anti-inflammatory roles; biliverdin is cytoprotective and antioxidative; and ferrous iron has indirect cytoprotective effects by inducing expression of antioxidative ferritin (Grochot-Przeczek et al. 2012) . In Alzheimer's, the level of cytotoxic heme increases and Hsp32 could aid in its conversion to beneficial antioxidant byproducts (Calabrese et al. 2010) . Cytoprotective effects of Hsp32 have been implicated in conditions including inflammatory diseases and ischemic damage (Calabrese et al. 2010; Gozzelino et al. 2010) . High concentration of heme has also been implicated as an injury factor in intracranial hemorrhage causing stroke (Lok et al. 2011 ). Hsp32 could be beneficial in alleviating this condition by converting heme to antioxidant byproducts. Hsp32 has been reported to have a protective role in cell death associated with neurodegeneration (Satoh et al. 2003; Li et al. 2007; GuzmanBeltran et al. 2008; Scapagnini et al. 2011) . This is of particular importance as an increase in heme in the cerebral cortex of the brains of Alzheimer's patients has been suggested to form heme-amyloid beta complexes leading to pathological symptoms (Pramanik and Dey 2011) . Hence, the ability of celastrol to induce a set of Hsps in cortical cells, including a robust induction of Hsp32, could be beneficial to counter Alzheimer's disease and also ameliorate the effects of heme-mediated damage in stroke. Our results indicate that celastrol can induce Hsp32 in immature cortical cultures at DIV6 and DIV10, in addition to induction in mature cortical cultures at DIV13. This suggests that celastrol may be a potential agent to induce this neuroprotective Hsp in the cerebral cortex of the immature developing brain and neonatal brain after ischemic or hypoxic damage. Recently, in vivo administration of celastrol in a transgenic mouse model of Alzheimer's disease has been shown to reduce a key neuropathological hallmark of this degenerative disorder, namely beta-amyloid pathology in the brain (Paris et al. 2010) .
